Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
India accounts for more than half (almost 60%) of new leprosy cases worldwide, despite being declared ‘leprosy-free’ in 2005.
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
Launched in the year 2018, MedEngage Scholarship Program is aimed at nurturing and nourishing medical talent in India
Clinical trials for minimally invasive therapy procedures using advanced imaging from Philips Lung Suite start with successful first cases
Veritaz has over 40 brands marketed across the acute and critical care therapeutic segments
The MoU proposed investments in hospitals, pharmacies and laboratories in the state
It also empowers domestic precision immunotherapy for tumours and promotes the high-quality development of China's biopharmaceutical industry
The implementation of ScienceMedia's solutions will ultimately help AMCR collapse patient recruitment and enrollment
The enhanced portfolio includes the Scenaria View, Supria series, The Echelon Smart and Arietta series
Subscribe To Our Newsletter & Stay Updated
